Denver has become the first city in the US to decriminalize psilocybin mushrooms. This is exceptionally inspiring news for millions of people nationwide suffering from depression and anxiety as studies show the mushrooms have the potential to help treat and alleviate mental illness.
In a very close race, votes were finally counted and posted this evening. Yesterday, May 7th, Denver voted in favor of a citizen initiative on the ballot that will make the possession, use and growth (but not sales) of psilocybin mushrooms for those over the age of 21 the city’s “lowest law-enforcement priority.” The city government would also be prohibited from using funds to impose criminal penalties against adults for low-level psilocybin offenses. In addition, the initiative would create a review panel to periodically report on the effects of the decriminalization.
Leading the way in the psychedelic revolution, Denver is helping to shape a wider view on such a powerful medicine, similar to the cannabis movement.
Decriminalize Denver, the citizen-led grassroots movement behind the campaign is dedicated to removing the unfounded restrictions on psychedelics. “As the first of its kind in the US, our ballot initiative serves as a framework for psilocybin mushroom legislative reform.”
The safety and efficacy of psilocybin has been proven time and again. In fact, rated the safest of all recreational drugs. Numerous studies highlighting the benefits of psilocybin are underway and thus far have presented exceedingly favorable results. This includes psilocybin as a treatment for cocaine and alcohol addiction, smoking, depression, cluster headaches, anxiety, and obsessive-compulsive disorder just to name a few.
Psilocybin is currently classified as a schedule 1 drug (a dangerous substance with high potential for abuse and no known medical potential), in the same category as heroin.
Although current research corroborates that psilocybin is a safe and efficacious treatment for many disorders, it must clear phase III clinical trials (which takes years) before the Food and Drug Administration can be petitioned to reclassify.